Enhanced Therapeutic Bacteriocins with Improved Efficacy and Stability

The present invention provides novel therapeutic bacteriocin compositions and methods with enhanced receptor-mediated translocation functionality, improved killing efficacy, and increased stability, offering a more effective and efficient solution for reducing microbial colonies and treating bacterial infections.

The original patent disclosed therapeutic bacteriocins with antimicrobial properties, but had limitations in terms of targeting multiple bacterial strains, killing efficacy, and stability. The present invention addresses these limitations by engineering bacteriocins with enhanced receptor-mediated translocation domains, improved cargo domains, and modified sequences to minimize degradation and immunogenicity.

The inventive concept comprises bacteriocin-based antimicrobial compositions with enhanced stability and shelf-life, engineered to target multiple Gram-negative bacteria strains simultaneously. The bacteriocins are designed with modified receptor-mediated translocation domains to reduce degradation by host enzymes and minimize immune system recognition. The compositions can be used to treat bacterial infections, prevent biofilm formation, and reduce microbial colonies. The inventive concept also encompasses methods for using these compositions, including methods for preventing biofilm formation and treating bacterial infections.

The new claims introduce novel and non-obvious features, including the use of bacteriocins with enhanced receptor-mediated translocation functionality, the combination of bacteriocins with distinct receptor-mediated translocation domains, and the modification of receptor-mediated translocation domains to reduce degradation and immunogenicity. These features provide a significant improvement over the original patent and offer a more effective and efficient solution for reducing microbial colonies and treating bacterial infections.

Alternative embodiments of the inventive concept could include the use of different bacteriocin sequences, varying the receptor-mediated translocation domains, or incorporating additional cargo domains. The inventive concept could also be implemented using different delivery mechanisms, such as topical application or oral administration.

The inventive concept has significant commercial potential in the fields of pharmaceuticals, biotechnology, and healthcare. The enhanced therapeutic bacteriocin compositions and methods could be used to treat a wide range of bacterial infections, including those caused by multidrug-resistant bacteria, and could provide a more effective and efficient solution for reducing microbial colonies and preventing biofilm formation.